Biotech Values

[zipjet]

MNTA - the question was always whether the patents would be valid. IF SO, there would be infringement.

The findings of fact, conclusions of law and the opinion should make interesting reading.

But for now the valuation of MNTA has to assume that there will be no mC launch until the patents expire.

With several years to go, there may be other competitors with a generic Copaxone. Worse yet, if BG12 gets approved (think it will and soon) and they price it competitively, it will have taken a big bite out of the MS market by 2015. IF BG12 is as good as it appears, and is priced competitively I suspect it could take half the market. I wonder if it will have a limited therapeutic life.

ij